Kura Oncology, Inc. (KURA) News
Track canonical SquawkNews coverage tagged to KURA, Kura Oncology, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 20 indexed stories across 12 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Kura Oncology Q2 2026 Earnings Call Transcript
On Wednesday, Kura Oncology (NASDAQ: KURA ) discussed second-quarter financial results during its earnings call. The full transcript is provided below. APIs provide real-time access to earnings call transcripts and finan
LIVE | Sep 17, 2026, 10:34 AM UTC
L
KURA: KOMZIFTI leads new patient starts in acute leukemia, with major data and expansion ahead
KOMZIFTI is rapidly gaining market share in acute leukemia, supported by strong efficacy, safety, and payer access. Multiple phase III trials and data updates are underway, with expansion into diabetes and solid tumors t
EQUITY | Sep 09, 2026, 02:46 PM UTC
L
KURA: Ziftomenib leads in acute leukemia with robust growth and pivotal data expected in 2028
Ziftomenib is driving market leadership in acute leukemia with strong commercial uptake and ongoing phase III trials, while darlifarnib advances in solid tumor combinations. The launch of Caspian Therapeutics enables exp
EQUITY | Sep 09, 2026, 02:21 PM UTC
M
Kura forms Caspian and retains 49.2% stake
Kura formed Caspian Therapeutics, contributed next-generation menin inhibitor assets and retained approximately 49.2% after a $50.0 million Series A financing.
REGULATION | Sep 09, 2026, 11:14 AM UTC
L
Kura Oncology launches Caspian Therapeutics with $50 million financing
Kura Oncology launched Caspian Therapeutics with $50 million financing to advance menin inhibition for diabetes.
EQUITY | Sep 09, 2026, 11:00 AM UTC
L
KURA: Strong commercial momentum and advancing late-stage pipeline position for major growth
KOMZIFTI's commercial launch is strong, with rapid revenue growth, broad market access, and majority share in its target population. Multiple late-stage studies are progressing, with key data readouts and regulatory mile
REGULATION | Sep 08, 2026, 09:22 PM UTC
L
KURA commercial momentum and late-stage pipeline seen advancing toward 2028
Komz?fti’s commercial launch is exceeding expectations, with strong revenue growth, majority market share in NPM1 mutant AML, and broad payer coverage. Multiple late-stage studies are progressing, with key data readouts
EQUITY | Sep 08, 2026, 08:51 PM UTC
L
Kura Oncology appoints Jennifer Fulk as chief financial officer
Kura Oncology hired Jennifer Fulk as its new chief financial officer. Fulk, 49, most recently served as chief financial officer of Soleno Therapeutics, and will receive an annual base salary of $550,000.
EQUITY | Sep 08, 2026, 11:24 AM UTC
L
Kura Oncology names Jennifer Fulk chief financial officer
Kura Oncology appointed Jennifer Fulk as chief financial officer, principal financial officer and principal accounting officer, effective September 8, 2026.
REGULATION | Sep 08, 2026, 11:13 AM UTC
L
Kura Oncology appoints Jennifer Fulk as Chief Financial Officer
Kura Oncology appointed Jennifer Fulk as Chief Financial Officer.
EQUITY | Sep 08, 2026, 11:01 AM UTC
L
Kura Oncology reports inducement grants under Nasdaq Rule 5635(c)(4)
Kura Oncology reported inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 11:30 AM UTC
L
Kura Oncology to participate in three investor conferences in September
Kura Oncology plans to participate in three investor conferences during September.
EQUITY | Sep 01, 2026, 11:15 AM UTC
M
KURA, FLNC, NVTS and NBIS lead premarket big-cap gainers
Premarket movers include KURA up 10% on an insider purchase, FLNC up 8% after a UBS upgrade to NEUTRAL, NVTS up 5% on a Claros acquisition plan, and NBIS up 4% after closing a convertible notes offering totaling about $5
EQUITY | Aug 25, 2026, 12:07 PM UTC
L
Citizens reiterates Market Outperform on Kura, sets $24 target
Citizens reiterates Market Outperform on Kura and sets a $24 price target after its Q2 update.
EQUITY | Aug 24, 2026, 12:12 PM UTC
L
KURA Posts Q2 2026 Results
KURA reports Q2 2026 financial results with KOMZIFTI revenue up 57%
EARNINGS | Aug 12, 2026, 08:09 PM UTC
L
Kura Oncology Reports Q2 2026 Financial Results
Kura Oncology reports second quarter 2026 financial results
EARNINGS | Aug 12, 2026, 08:02 PM UTC
L
KURA - Kura Oncology to Report Second Quarter Financial Results
KURA - Kura Oncology to Report Second Quarter Financial Results
EARNINGS | Aug 05, 2026, 11:30 AM UTC
L
KURA Reiterate Market Outperform, $24 PT after investor event @ Citizens
KURA Reiterate Market Outperform, $24 PT after investor event @ Citizens
EQUITY | Jul 28, 2026, 11:33 AM UTC
L
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq
EQUITY | Jul 03, 2026, 11:30 AM UTC
H
Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript
Kura Oncology (NASDAQ: KURA ) released first-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This content is powered APIs. For comprehensive financial data and transc
CENTRAL_BANK | Jul 02, 2026, 06:08 AM UTC